General Federal Contracts — February 03, 2026

Dual wins ($277M GSA border facility + $180M NIH lab) fully obligated through 2028, with 12% avg outlay signaling early progress.

$366M to GDIT ($196M, 51% outlayed) and Emmes ($169M, 70% outlayed) for CMS/NIAID support through 2027, highlighting stable health IT/data flows.

$304M HHS award for biological manufacturing has $72M unexercised options to 2028, despite low 4% outlay.

Firm fixed price exposes to cost overruns in $457M Hensel Phelps construction projects amid design-build complexities.

Long tenors to 2028 (all contracts) vulnerable to HHS/GSA budget shifts or audits on cost-plus structures.

Low initial outlays (avg <10% in 2/5 contracts) signal potential ramp-up delays.

$189M unexercised options across ATI ($72M) and Emmes ($117M) for health R&D expansion.

NIH/NIAID lab and infectious disease focus positions winners for follow-on federal health infrastructure.

75% of value ($849M) funds lab expansions, biological manufacturing, and data services through 2028.

$457M firm-fixed awards to Hensel Phelps for labs/border facilities highlight full obligation trends.

{"entity"=>"Hensel Phelps Construction Co.", "reason"=>"$457M dual wins represent 40% of period value with full obligations to 2028.", "trigger"=>"additional HHS/GSA awards or outlay >30% YoY"}

{"entity"=>"ADVANCED TECHNOLOGY INTERNATIONAL", "reason"=>"Largest single award ($304M) at 4% outlay flags ramp-up uncertainty.", "trigger"=>"outlays exceeding $50M in next 12 months"}

{"entity"=>"THE EMMES COMPANY, LLC", "reason"=>"70% outlay on $169M NIAID contract with $117M options to 2028.", "trigger"=>"option exercises or extension to 2028"}